Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to tolerate, ...
REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 ...
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition. “Ulcerative colitis is a complex, lifelong ...
Simponi is also prescribed to treat ulcerative colitis in adults. And Simponi Aria is also prescribed to treat PsA and polyarticular juvenile idiopathic arthritis in some children. Simponi and Simponi ...
rheumatoid arthritis and ankylosing spondylitis in adults psoriatic arthritis in adults and children ages 2 years and older polyarticular juvenile idiopathic arthritis in children ages 2 years and ...
Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...
LEIDEN, The Netherlands, Sept. 23, 2013 /PRNewswire/ -- Janssen Biologics B.V. ("Janssen") announced today that the European Commission has approved SIMPONI® (golimumab) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback